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Cholesterol impairment contributes 
to neuroserpin aggregation
Costanza Giampietro1,*, Maria Chiara Lionetti2,*, Giulio Costantini3, Federico Mutti2, 
Stefano Zapperi3,4,5,6 & Caterina A. M. La Porta2
Intraneural accumulation of misfolded proteins is a common feature of several neurodegenerative 
pathologies including Alzheimer’s and Parkinson’s diseases, and Familial Encephalopathy with 
Neuroserpin Inclusion Bodies (FENIB). FENIB is a rare disease due to a point mutation in neuroserpin 
which accelerates protein aggregation in the endoplasmic reticulum (ER). Here we show that 
cholesterol depletion induced either by prolonged exposure to statins or by inhibiting the sterol reg-
ulatory binding-element protein (SREBP) pathway also enhances aggregation of neuroserpin proteins. 
These findings can be explained considering a computational model of protein aggregation under 
non-equilibrium conditions, where a decrease in the rate of protein clearance improves aggregation. 
Decreasing cholesterol in cell membranes affects their biophysical properties, including their ability to 
form the vesicles needed for protein clearance, as we illustrate by a simple mathematical model. Taken 
together, these results suggest that cholesterol reduction induces neuroserpin aggregation, even in 
absence of specific neuroserpin mutations. The new mechanism we uncover could be relevant also for 
other neurodegenerative diseases associated with protein aggregation.
Conformational diseases, such as Alzheimer’s and Parkinson’s diseases, spongiform encephalopathies and ser-
pinopathies, are an increasingly common class of neurological disorders characterized by the aggregation of 
aberrant conformations of proteins. Familial Encephalopathy with Neuroserpin Inclusion Bodies (FENIB)1,2 is 
an autosomal dominant inclusion body dementia characterized by protein aggregation within the endoplasmic 
reticulum (ER)1,2. FENIB is associated with mutations in neuroserpin3, a protein belonging to the superfamily 
of serpins that plays an important role in brain development, neuronal survival, and synaptic plasticity4. Indeed, 
mutants of neuroserpin in FENIB patients show accelerated rates of polymerization compared with wild type 
proteins, both at the protein level in vitro5,6 and in cell models1,2. Moreover, neuroserpin is the most important 
inhibitor of the tissue plasminogen activator (tPA) in the brain which is known to be increased in Alzheimer’s 
disease7–9.
Lipid metabolism has been shown to play a role in FENIB, but also in other neurodegenerative diseases, 
from Alzheimer’s to Parkinson’s disease10–13. In FENIB the inhibition of hydroxymethyl glutaryl-CoA reductase 
(HMGCR) has a critical role in the clearance of mutant neuroserpin from the ER13. Numerous studies have also 
reported that the modification of cholesterol content can affect amyloid precursor protein (APP) processing, 
which is needed for neuronal activity11. In this connection, it has been shown that the E693D (Osaka) mutation in 
APP promotes intracellular accumulation of Amyloidβ (Aβ), thus disturbing amyloid-mediated cholesterol efflux 
from the cell14. Cholesterol has also been shown to influence APP processing and Aβ generation by modulating 
Aβ- and Amyloid-γ-secretase activities15–18. In turn, APP cleavage products regulate cholesterol homeostasis19.
In a recent paper, our group has shown by 3D numerical simulations and mean-field calculations that protein 
aggregation undergoes a non-equilibrium phase-transition controlled by the rates of protein synthesis and degra-
dation, suggesting a crucial role of intracellular trafficking, particularly from the ER20. According to this study, a 
decrease in the rate of protein clearance from the ER can lead to rapid and irreversible protein aggregation in the 
ER itself20, leading to the onset of neurodegenerative diseases.
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Cholesterol plays a crucial role in regulating the properties of phospholipid membranes, affecting their fluidity 
and rigidity21–23, the function and dynamics of membrane proteins24,25, and thus vesicular trafficking within the 
cell26–28. Hence, by regulating the biosynthesis of cholesterol it is possible to affect the form and function of all the 
membranes within the cell, including the ER. In particular, experiments show that lowering the level of choles-
terol delays ER-to-Golgi transport28,29.
Cholesterol homeostasis is controlled by a family of transcription factors, known as sterol regulatory ele-
ment binding proteins (SREBPs)30. In cells with sufficient cholesterol supply, SREBPs are transmembrane pro-
teins retained in the ER, associated with SREBP-cleavage-activating protein (SCAP), a cholesterol sensor31. Upon 
cellular cholesterol depletion, SREBP leaves the ER to reach the Golgi, where cleavage by site-1 protease (S1P) 
releases the amino-terminal half of SREBP, which can be further cleaved within its membrane-spanning helix by 
site-2 metalloproteinase (S2P)32. The mature processed form of SREBP is released in the cytosol and can trans-
locate into the nucleus where it modulates the expression of several genes controlling cholesterol and fatty acid 
homeostasis33, including HMGCR, HMG-CoA synthase (HMGCS), low density lipoprotein receptor (LDLR) and 
SREBP1/2 itself. SREBP1 activates fatty acid synthesis and SREBP2 cholesterol synthesis and uptake34.
In this paper, we combine experiments and computational analysis to show that lowering the level of cho-
lesterol either by using statins or by inhibiting SREBP1 and SREBP2 pathways with the small molecule betulin 
has a significant impact on the aggregation of non-mutated neuroserpin within the cell. Statins are competitive 
inhibitors of HMGCR, a rate limiting enzyme for cholesterol levels. They are widely used as plasma cholesterol 
lowering drugs in dyslipidemic patients. In spite of the clear effect of statins in lowering morbidity and mortality, 
in particular in cardiovascular events, many recent studies suggest that prolonged use of statins in Alzheimer’s 
disease patients leads to mixed outcomes and could contribute to statin-adverse effects35–39. Whereas current 
guidelines encourage an aggressive use of statins to achieve long-term cholesterol lowering in order to decrease 
cardiovascular events, the resulting effect on cell membranes is unknown. Here, we focus our experimental anal-
ysis on non-mutated (wild type) neuroserpin and directly observe a dramatic increase in aggregates when cells are 
chonically exposed to statins. To confirm the direct involvement in aggregation of lower cholesterol levels, we use 
betulin, a pentacyclic triterpene commonly isolated from the birch bark, that specifically inhibits the maturation 
of SREBPs by enhancing interaction between SCAP and INSIG thus promoting SREBPs retention in the ER40. 
Also in this case, we observe lower cholesterol and more neuroserpin aggregation. Our findings are consistent 
with a cholesterol induced decrease in the protein clearance rate, leading to faster aggregation in our model20. To 
elucidate the biophysical mechanism underlying this observation, we study a mathematical model of coated vesi-
cle release from lipid membranes, illustrating the crucial role of cholesterol for vesicle formation and therefore the 
impact of its unbalance on intracellular trafficking. Taken together, our results suggest that long-term treatment 
with statins may affect intracellular trafficking in a way to enhance protein aggregation.
Results
Prolonged treatment with statins enhances neuroserpin aggregation in HeLa cells. Simvastatin 
(SIM), pravastatin (PRA) and rosuvastatin are all known to be inhibitors of cholesterol synthesis by acting on 
HMGCR. PRA is, however, reported to be less effective both in patients and in vitro due to its hydrophylicity41. 
We test the effect of long-term (i.e. up to 8 days) treatment with statins (5 μM SIM or 10 μM PRA or 0.1 μM rosu-
vastatin or 1 μM rosuvastatin) on the capability of neuroserpin to aggregate in HeLa cells. Figure 1a shows that, 
in native gel, the treatment with SIM is able to induce multiple bands of neuroserpin, suggesting the presence of 
aggregates. We obtain similar results for the more powerful drug rosuvastatin, as reported in Fig. 1b 42. In con-
trast, the exposure to PRA does not affect neuroserpin aggregation, as shown in Fig. 1a. To directly confirm the 
presence of neuroserpin aggregates after prolonged treatment with statins, we use the Duolink in Situ staining. 
Using this technique allows the detection of a fluorescent spot if at least two monomers of neuroserpin protein 
are in close proximity, such as when they form a dimer. We mix (1:1) HeLa with HeLa-GFP cells to confirm that 
possible aggregation is independent from the specific cell line used. Moreover, in HeLa—GFP cells the cytoplasm 
is green. We then treat the cells with statins for up to 8 days. Long-time treatment (8 days) with 5 μM SIM or 
0.1 μM rosuvastatin induces neuroserpin aggregation while shorter incubation times with 5 μM SIM or 8 days 
of treatment with 10 μM PRA do not induce any effect, as shown in Fig. 2. Moreover, 8 days of treatment with 
0.1 μM rosuvastatin gives a stronger effect with respect to 5 μM SIM Figs 2 and 3.
Effect of the treatment with SIM, rosuvastatin or PRA on cholesterol and HMGCR levels in 
HeLa cells. Filipin is commonly used to detect cholesterol, but it is not very stable, rapidly photobleaches 
and results in acute toxicity for living cells43. To avoid these problems, we use a fluorescently labeled theonel-
lamide (TNM-AMCA). TNM-AMCA was originally isolated from a marine sponge, and has been reported to 
bind in a specific manner to the 3β-hydroxyl group of cholesterol without acute toxicity44–46. 5 μM SIM, 0.1 μM 
rosuvastatin or 20 μM betulin affect the level of cholesterol after 8 days of treatment (Figs 3 and 4), while PRA is 
less effective and does not change significantly the level of cholesterol41 (Fig. 4). Finally we investigate by west-
ern blot whether the treatment with statins affects the expression level of the key enzyme of cholesterol synthe-
sis, HMGCR. As shown in Fig. 1c, no significant changes in the level of expression of this enzyme occurs after 
long-time treatment either with SIM or PRA.
Effect of the treatment with SIM, rosuvastatin or PRA on the level of expression of SREBP1 
and SREBP2. SREBPs are transmembrane proteins expressed at the level of ER, associated with SCAP which 
is a cholesterol sensor31. Intracellular trafficking of SREBPs is sensitive to cholesterol depletion: when the level 
of cholesterol is reduced, SREBP leaves the ER to reach the Golgi where it is cleaved. Then, the mature processed 
form of SREBP is released in the cytosol and translocates into the nucleus where it modulates the expression of 
several genes controlling cholesterol and fatty acid homeostasis33 and SREBP1/2 itself. Furthermore, it is known 
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that SREBP1 regulates fatty acid synthesis and SREBP2 cholesterol synthesis and uptake34. We thus investigate by 
immunofluorescence the effect of statins on the level of expression of SREBP1 and SREBP2. Figure 5 shows that 
SREBP1 is not affected by the either SIM or PRA treatments and SREBP2 increases significantly after 8 days of 
treatment with SIM. Rosuvastatin, in contrast, affects mainly SREBP1 (Fig. 6a).
Effect of the treatment with betulin on the level of expression of cholesterol, neuroserpin 
aggregation, SREBP1 and SREBP2. An alternative route to interfere with the cholesterol level and study 
its effect on neuroserpin aggregation is to inhibit SREBPs activity using betulin, a small molecule that is known 
to inhibit the maturation of SREBP by inducing interaction of SCAP and Insig40,47. Betulin induces a decrease of 
cholesterol after 8 days of treatment (Fig. 3)40 and an accumulation of the precursor of SREBPs (pre-SREBP), in 
agreement with refs 48,49 (Fig. 6b). Under these conditions, we show that the treatment for 8 days with 20 μM 
betulin induces neuroserpin aggregation (Figs 1 and 3a).
Computational simulations reveal aggregation induced by the impairment of intracellular traf-
ficking. In a previous paper our group developed a model three dimensional to explain the critical role for 
protein aggregation of the non-equilibrium conditions in the ER20. Here we implement the model in order to 
understand how the impairment of intracellular trafficking might induce protein aggregation. The model per-
forms coarse—grained simulations of diffusing monomers and polymers in a closed system, representing the 
ER, under a constant rate of protein production kin. Proteins exit the ER with a rate kout when they are close to the 
boundaries simulating vesicular trafficking. Hence, the parameter kout encapsulates the efficiency of intracellular 
trafficking which can be affected by the level of cholesterol in the cell. Figure 7a shows that reducing kout, which 
should simulate an impairment in the intracellular trafficking leads to an increase in protein aggregation, thus 
recapitulating in silico the experimental observations.
Mathematical model illustrates mechanical regulation of vesicle formation. The mechanism by 
which the level of cholesterol determines the value of kout is related to its role in affecting the biophysical proper-
ties of membranes21–25 and thus their ability to form the vesicles needed for intracellular trafficking26–28. Vesicle 
formation in the ER is assisted by the Coat protein complex II (COPII) that is recruited on the surface of the ER 
membrane50. The COPII complex self-assembles into a cage structure that encapsulate the lipid membrane form-
ing a vesicle51. The success of the process crucially depends on the binding strength of the COPII to the mem-
brane and on its bending stiffness, as we can illustrate by a simple mathematical model. We considers an elastic 
membrane coupled to a curvature induced coat, representing the action of a COPII cage in the ER. The model, 
described in details in the methods section includes two key dimensionless parameters: (i) the ratio between 
the bending stiffness of the membrane Km and the one of the coating scaffold Ks, and (ii) the ratio between the 
scaffold bending energy and its interaction energy with the membrane εLJ. Simulations show that vesicle can only 
form is Km/Ks is small and εLJ/Ks is sufficiently large. For larger values of Km/Ks, the coating scaffold is not able to 
Figure 1. Aggregation of neuroserpin with statins or botulin. (a) 100 μg protein of HeLa cells or treated 
with 10 μM PRA or 5 μM SIM or 0.1 μM rosuvastatin or 1 μM rosuvastatin or 20 μM betulin were loaded on 
10% native gel and transferred on PVDF membrane. The sheet was incubated with anti-neuroserpin (ab32901, 
Abcam, 1:500) overnight at 4 °C and then with the secondary antibody anti goat-HRP (1:5000, ECL Blotting 
reagents (GE Healthcare RPN2109)/SuperSignal West Femto Maximum Sensitivity Substrate, Thermo 
scientific) for 1 h at room temperature. Ponceau S solution (P7170, Sigma) was used to verify the correct loading 
of the samples. (b) Effect of statins or betulin treatments on the level of expression of neuroserpin or HMGCR. 
10 μg total protein were loaded on 10% polyacrilamide gel, transferred on PVDF and incubated with anti-
neuroserpin (ab32901, AbCAM, 1:500) or with anti-HMGCR (1:1000, MAB5374, Millipore) overnight at 4 °C). 
Vinculin (1:10000, Sigma) was used as housekeeping.
www.nature.com/scientificreports/
4Scientific RepoRts | 7:43669 | DOI: 10.1038/srep43669
bend the membrane into a vesicle while if εLJ/Ks is small the coat detaches from the membrane. This behaviour is 
summarized in the phase diagram reported in Fig. 7b. A reduction in the level of cholesterol in the ER membrane 
affects both Km21–23 and εLJ29, thus displacing the system in different regions of the phase diagram. In particular, 
experiments show that cholesterol depletion leads to a reduced recruitment of the Sec23p component of the 
COPII complex on the ER membrane, delaying ER-to-Golgi transport29.
Discussion
Long-term lowering serum low density lipoprotein cholesterol with statin drugs is used extensively and has 
proven very effective to reduce the incidence of cardiovascular events. De-novo cholesterol which is the target of 
statin therapy is found in all membranes and lipid based bodies, contributing to vesicle formation and migration, 
as well as other membrane functions52. We can therefore expect that regulating the biosynthesis of cholesterol 
could change the form and function of every membrane within the cell. For this reason, statin therapies could also 
Figure 2. Duolink In situ Staining of neuroserpin in HeLa untretaed or treated with SIM or PRA. (a) 
Hela-GFP and Hela cells were mixed 1:1 and treated with 5 μM SIM or 10 μM PRA up to 8 days, fixed in 3.7% 
paraformaldeide and incubated with the primary antibody anti-neuroserpin (Ab32901, Abcam) coniugated 
PLA probes (1:50), overnight at 4 °C. The presence of aggregates are visualized using Duolink in Situ staining 
according to the manufacturer’s instructions. Nuclei are stained with DAPI. Images are acquired by Leica SP2 
laser scanning confocal microscope. Each red spot represents a neuroserpin aggregate. (b) The number of spots 
per cell for each condition reported in panel a is quantified as described in the methods section.
www.nature.com/scientificreports/
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cause potential harm53. The role of ER in the aggregation of misfolded proteins, such as neuroserpin, and there-
fore as a crucial determinant of cellular toxicity, is important in many neurodegenerative diseases. Our group 
recently demonstrated the presence of a phase transition towards rapid protein aggregation due to a breakdown 
Figure 3. Effect of rosuvastatin and betulin on neuroserpin aggregation and cholesterol level. (a) Hela-
GFP and Hela cells were mixed 1:1, treated with 0.1 μM rosuvastatin or 20 μM betulin for 8days, fixed in 3.7% 
paraformaldeide and incubated with the primary antibody anti-neuroserpin (Ab32901, Abcam) coniugated 
PLA probes (1:50), overnight at 4 °C. The presence of aggregates are visualized using Duolink in Situ staining 
according to the manufacturer’s instructions. Nuclei are stained with DAPI. Images are acquired by Leica 
SP2 laser scanning confocal microscope. Each red spot represents a neuroserpin aggregate. The number of 
spots per cell for each condition in the images showed in this panel is quantified as described in the methods 
section. (b) Untreated or treated cells with 0.1 μM rosuvastatin or 20 μM betulin (8 days) were fixed with 3.7% 
paraformaldeide and then incubated with TNM-AMCA (1 μM) to stain cholesterol for 1 h at room temperature. 
Images were acquired by Leica SP2 laser scanning confocal microscope.
Figure 4. Detection of cholesterol with TNM-AMCA in untreated and treated HeLa cells after statins 
treatments. Untreated or 5 μM SIM or 10 μM PRA treated HeLa cells for the time reported in the figure, were 
fixed with 3.7% paraformaldeide and then incubated with TNM-AMCA (1 μM) to stain cholesterol for 1 h at 
room temperature. Images were acquired by Leica SP2 laser scanning confocal microscope.
www.nature.com/scientificreports/
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of homeostasis in intracellular organelles, such as the ER, controlled by the rates of protein synthesis and clear-
ance, kin and kout, respectively20. The open question stated in the conclusions of our earlier paper was related 
to the identification of possible biological processes and factors that would tune these key parameters into an 
aggregation-prone pathological phase20. In the present paper, we combine experiments and computational mod-
els to investigate this critical issue.
We focus our attention on cholesterol depletion by statins as a potential inhibitor protein clearance from 
the ER. We investigate three different statins in a chonic treatement (8 days): SIM, rosuvastatin and PRA. 
Rosuvastatin has been shown to be more effective than SIM42, while PRA is less effective when compared with 
SIM41. Here we show indeed that long-term treatment with SIM or rosuvastatin decreases the level of cholesterol, 
increases the level of expression of SREBP, compensating for cholesterol depletion, and finally enhances neuros-
erpin aggregation even in the absence of specific mutations. In contrast, PRA is less effective than the others two 
statins and therefore does not affect neither the level of cholesterol nor neuroserpin aggregation41.
To ensure that the aggregation we observe for neuroserpin is really due to the lowering of cholesterol in the cell 
rather to a direct interaction between statins and neuroserpin, we interfere with the cholesterol level indirectly by 
targeting SREBP through betulin, whose action ultimately leads to cholesterol depletion40. We found that betulin 
decreases the level of cholesterol and accumulates pre-SREBPs40,48,49. Also in this case, we find an enhancement of 
neuroserpin aggregation after long term treatment (8 days).
It is well known that N-glycosylation plays determinant roles in protein folding and trafficking, and 
N-glycosylated proteins are especially important in regulating extracellular activities. Recent papers show that 
Figure 5. Level of expression of SREBP1 and SREBP2 after SIM or PRA treatment in Hela cells. 
Subconfluent cells are fixed with 3.7% paraformaldeide after 8 days treatment with statins and incubated 
with anti-SREBP1 (1:100, ab28481) or anti SREBP-2 (1 μg/ml ab30682, Abcam) overnight at 4 °C. Next, the 
cells are incubated with anti-rabbit Alexa Fluo488 for 1 h at room temperature. Actin is stained with 1 μg/ml 
Actistain-555 phalloidin for 1 h at room temperature. Nuclei are stained with DAPI. Untreated cells are also 
shown for reference. Images are acquired by Leica SP2 laser scanning confocal microscope.
www.nature.com/scientificreports/
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aberrant N-glycosilation happens frequently in relation to human diseases, including Alzheimer’s54 and FENIB, 
as pointed out in a recent paper55. Furthermore, a systematic and quantitative analysis of surface proteins was 
carried out in HepG2 liver cells treated with statin showing that many glycosilation sites are downregulated com-
pared to untreated cells56. On the other hand, statins inhibit the pathway of dilichol, which plays a critical role 
in protein N-glycosilation and acts as a membrane anchor for the formation of a precursor oligosaccharide57. 
Therefore, the long-treatment with statins could lead to important impairment of intracellular trafficking, effec-
tively decreasing the clearance rate kout20. This is shown directly by numerical simulations of a protein aggregation 
model where reducing kout leads to faster aggregation.
The role of cholesterol on the biophysical properties of lipid membranes has been the subject of extensive 
experimental investigation. It is known that the level of cholesterol affects the membrane bending stiffness Km21–23 
the dynamics of membrane proteins24,25 and has thus an effect on vesicle formation and trafficking26–28. In particu-
lar, experiments show that the attachment of coating proteins, such as COPII, to membranes is dependendent on 
cholesterol29. Here, we develop simple mathematical model that can incorporate into a single framework all this 
experimental observations and help predict the effect of statins on the intracellular trafficking. While the model 
is too simple to provide a quantitative explanation of vesicle formation in dependence on the cholesterol level, 
the phase diagram illustrates the possibility that small changes of key membrane biophysical parameters such as 
the bending stiffness or the binding affinity of coat proteins, all known to be affected by cholesterol, result in a net 
impairment of vesicle formation.
Recent results in the literature show an increased level of neuroserpin in Alzheimer’s disease patients, the 
critical role of tPA and the association between neuroserpin and Aβ plaques in Alzheimer’s brain tissues58. Our 
paper shows that neurosperpin aggregation can be modulated by environmental factors affecting intracellular 
trafficking, even in the absence of deleterious mutations that are known to induce aggregation1,2,5,6. The aggre-
gation mechanism we propose is fairly general, depending only on the modification of kinetic rates for protein 
clearance and it could therefore be relevant also for other neurodenerative pathologies. For instance, it would be 
extremely interesting to clarify the possible role of statins in Aβ aggregation and more generally on the develop-
ment of Alzheimer’s disease.
Methods
Cell lines and treatments. Human Hela cells (ATCC-CRL-2) or HeLa-GFP cells (AKR-213 Cell Biolabs 
Inc.) were cultured in 80%DMEM, 10% FBS with the addition of 1% antibiotics and 1% L-glutamine at 37 °C/5% 
CO2. SIM (S-6196, Sigma) needs to be activated by opening of the lactone ring before use in cell culture. We used 
the protocol described by59. Briefly, 40 mg/ml of SIM were dissolved in 100% ethanol with subsequent addition 
Figure 6. (a) Level of expression of SREBP1 and SREBP2 after rosuvastatin or betulin treatment in Hela cells. 
Subconfluent cells a fixed with 3.7% paraforldeide after 8 days of rosovastatin (0.1 μM) or betulin (20 μM) 
treatment and incubated with anti-SREBP1 (1:100, ab28481) or anti SREBP-2 (1 μg/ml ab30682, Abcam) 
overnight at 4 °C. Then, the cells are incubated with anti-rabbit AlexaFluo488 for 1 h at room temperature. 
Nuclei are stained with DAPI. Untreated cells are also shown for reference. Images are acquired by Leica SP2 
laser scanning confocal microscope. (b) Western blot of SREBP1 and SREBP2 in Hela cells untreated and after 
8 days of treatment with (20 μM betulin. 10 μg total protein were loaded on 10% polyacrilamide gel, transferred 
on PVDF and incubated or anti-SREPB1 (1:500, ab28481, AbCam) or anti-SREBP2 (1:100, ab30682, AbCam) 
were used overnight at 4 °C. Mouse anti-alpha Tubulin antibody (1:5000, Sigma) for 1 h at room temperature 
was used as housekeeping. A secondary antibody anti goat-HRP (1:5000, ECL Blotting reagents (GE Healthcare 
RPN2109)/SuperSignalTM West Femto Maximum Sensitivity Substrate, Thermo scientific) was used for 1 h at 
room temperature to detect chemiluminiscence. The bands reported are the precursor of SREBP1 and SREBP2, 
pre-SREBP.
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of 0.1 N NaOH59. The solution was heated at 50 °C for 2 h and then neutralized with HCl to pH 7.2. The resulting 
solution was bought to a final volume (1 ml) with distilled water and aliquots were stored at − 80 °C for no more 
then 3 months. Rosuvastatin (SML1264, Sigma) was dissolved in DMSO stock solution (20 mM) and stored in 
aliquots at − 20 °C. Pravastatin (P4498 Sigma) was dissolved in distilled water and stored in aliquots at − 80 °C. 
Betulin (B9757, Sigma) was dissolved in 100% etanol (500 μM) and stored in aliquots at − 20 °C. The medium has 
been replaced every 4 days with fresh medium containing statins or betulin or fresh medium for untreated cells.
Immunofluorescence. Subconfluent cells were fixed with 3.7% paraformaldeide, incubated with 0.1%Triton 
X-100 in PBS for 15 min at room temperature, then with 3%BSA in PBS for 30 min at room temperature and 
finally with anti-SREBP-1 (1:100, ab28481 Abcam. 3.7% PFA fixed cells were incubated with 1% BSA/10% goat 
serum/0.3 M glycine/0.1% tween in PBS for 1 h at room temperature and incubated with anti-rabbit (1:250, Alexa 
Fluor 488, ab 150077) for 1 h at room temperature. 1 μg/ml Actinstain-555 phalloidin (Cytoskeleton Inc) is used 
to stain actin for 1 h at room temperature. The nuclei were counterstained with DAPI and the slides mounted 
with Pro-long anti fade reagent (Life technologies). The images were acquired with a Leica TCS NT confocal 
microscope.
Figure 7. Numerical simulations show protein aggregation induced by impairment of trafficking. (a) The 
main figure shows the average number of aggregates observed at a fixed time as a function of kout/kin, the ratio 
between rate of exit from the ER by means of vesicular transport and the rate of protein production. A reduced 
value of kout leads to the formation of aggregates. The inset shows the time dependence of the average number of 
aggregates for different values of kout. (b) The phase diagram of the vesicle formation model. The stiffness ratio 
between the membrane and the external scaffold Km/Ks as a function of the intensity of the mutual interaction 
with respect to the scaffold rigidity εLJ/Ks. For soft membranes there is almost always vesicle formation (yellow 
zone) or the breaking of the coat-membrane interface, if binding is not strong enough (white zone). Increasing 
the membrane stiffness leads to a new phase appears where the coat-membrane interface is stable but vesicle can 
not form (grey zone). Typical configurations in the different phases are reported on the right-hand side of the 
panel.
www.nature.com/scientificreports/
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Duolink assay. Subconfluent cells were fixed with 4% paraformaldeide and incubated with 0.1%Triton X-100 
in PBS for 15 min at room temperature, then with 5%BSA in PBS for 1 h at room temperature and finally incu-
bated with anti-neuroserpin (ab32901 AbCam) coniugated PLA probes (1:50) overnight at 4 °C. We detected 
neuroserpin aggregates with Duolink In Situ staining. The Duolink In Situ staining are based on in situ PLA, 
which is a proximity ligation assay technology. A pair of oligonucleotide labeled secondary antibodies (PLA 
probes) generates a signal only when the two PLA probes have bound in close proximity (at a distance of less than 
40 nm), either to the same primary antibody or to two primary antibodies bound to the sample in close proximity. 
The signal from each detected pair of PLA probes is visualized as an individual fluorescent spot. Duolink In Situ 
Probemaker PLUS enables quick and convenient conjugation of the PLA PLUS oligonucleotide arm directly to 
the primary antibody (DUO92009 and DUO92010 for PLUS and MINUS probe). The cross reacted proteins were 
detected according to the manufacturer’s instruction (sigma.com/duolin, section 7.3 Detection protocol). The 
nuclei were mounted with Duolink in situ mounting medium containing DAPI (DUO82040, Sigma). The images 
were acquired with a Leica TCS NT confocal microscope. These PLA signals were quantified as described in the 
section spot detection.
Cholesterol staining. Cells were fixed with 4% paraformaldehyde (PFA) in PB 0.1 M for 10 minutes at 
room temperature (RT). Then, they were incubated with 50 μg/ml Digitonin for 5 minutes and then for 1 hour 
with 4% Bovine Serum Albumin (BSA) in PBS. The cells were then incubated with TNM-AMCA (1 μM, gently 
gifted by Shinichi Nishimura and Minoru Yoshida, RIKEN Center for Sustainable Resource Science, Saitama, 
Japan) for 1 hour. All the specimens were mounted with Fluoromount Aqueous Mounting Medium without DAPI 
(Sigma-F4680) and the images were acquired with Leica SP2 laser scanning confocal microscope.
Western Blot. Confluent cells were lysed by boiling in a modified Laemmli sample buffer (2% SDS, 20% 
glycerol, and 125 mM Tris-HCl, pH6.8). The protein concentration was measured by BCA Protein Assay Kit 
(Thermo Scientific). Equal amount of proteins were loaded on gel and separated by SDS-PAGE and transferred 
to a PVDF membrane (Whatman). After blocking, primary and HRP-linked secondary antibodies, specific bind-
ings were detected by chemiluminescence system (GE Healthcare). Goat polyclonal antibody anti-neuroserpin 
(1:500, ab32901, AbCAM) or rabbit anti-HMGCR (1:1000, MAB5374, Millipore) or anti-SREPB1 (1:500, 
ab28481, AbCam) or anti-SREBP2 (1:100, ab30682, AbCam) were used overnight at 4 °C. Mouse anti-vinculin 
(1:10000, V9264, Sigma) or anti-alpha Tubulin antibody (1:5000, Sigma) for 1 h at room temperature was used as 
housekeeping. A secondary antibody anti goat-HRP (1:5000, ECL Blotting reagents (GE Healthcare RPN2109)/
SuperSignalTM West Femto Maximum Sensitivity Substrate, Thermo scientific) was used for 1 h at room temper-
ature to detect chemiluminiscence.
For non denaturating gels, cells were resuspended in 50 mM Tris-HCl, pH7.4 containing 5 mM EDTA, 1% 
Triton-X100 and Protease inhibitors cocktail (1 ml/100 ml lysate, P8340, Sigma), passed for 4 times through an 
insulin syringe and maintained in ice for 20 min. After a brief centrifugation, the protein concentration was meas-
ured by BCA Protein Assay Kit (Thermo Scientific). 100 μg protein were loaded on 10% non denaturating gel, 
transferred on PVDF membrane as described above. The PVDF membrane was reversible stained with Ponceau 
S solution (P7170, Sigma) to verify the correct loading of the samples.
Spot detection. Image analysis of Duolink In Situ staining was performed using the bioimage informatics 
platform Icy60. To detect spots, we first use the Thresholder plugin to eliminate the random noise in the images. 
We used the automated mode so that the algorithm automatically calculates the optimal threshold value. We then 
applied the Spot Detector plugin61 that is based on an UnDecimated Wavelet Transform tool designed to detect 
spots. Then, we used the default values, enabling the scale = 2 setup with a threshold equal to 100 and a size filter 
to accept only spots with a size bigger than three pixels. We also extracted the number of cell nuclei and compute 
the ratio between the number of spots and the number of cells.
Statistical Analysis. Statistical significance analysis is performed using the Kolmogorov-Smirnov test.
Polymer aggregation model. Simulations are performed using the protein aggregation model described 
in ref. 20 where individual protein molecules sit on a three dimensional cubic lattice. Monomers diffuse with rate 
kD and attach to neighboring monomers or polymer endpoints with rate kH. Polymers move collectively by repta-
tion with a length-dependent rate kR/i2, where i is the number of monomers in the polymer, and locally by end 
rotations, with rate kE and kink motions with rate kK. A polymer can attach to another polymer with rate kH if 
their endpoints meet, and can fragment by breaking an internal bond with rate kf. Inspired by experimental 
results on neuroserpin polymerization62, we allow for polymerization after at least one of the monomers has been 
activated with rate kA. Active monomers can also become latent with rate kL and after that they do not aggregate. 
We consider a system of size (L× L× H) with L = 100L0 and H = 25L0, where L0 is the linear size of a monomer, 
with periodic boundary conditions along x and y and closed boundary conditions along z. Monomers enter the 
system from both closed boundaries with rate kin and monomers and polymers can exit from the same boundaries 
with rate kout/i3. Numerical simulations are performed using Gillespie Montecarlo algorithm63. We measure time 
in units of 1/kin and set = = = = =k k k k k kH E R K A in, kL = 0, =k k10D
2
in, =
−k k10f
3
in and vary kout.
Vesicle formation model. We consider a simple model with three basic interaction energies: two bending 
energies related, respectively, to the elasticity of the membrane and external cage, and a potential representing 
their mutual interaction. The membrane is modeled by a polygon with Nm nodes connected by inextensible bonds 
and resisting bending through an angular spring of energy
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2
where the parameter θ0 = θm = 0 is the equilibrium value of the angle between two bonds, and K = Km is the bend-
ing stiffness of the membrane. The coating scaffold is modeled, instead, as an open polygon with Ns nodes, rigid 
bonds and a bending energy given by eq. 1 with K = Ks and θ0 = θs ≥ 0. In order to simulate a realistic structure, 
we chose Nm/Ns = 10, corresponding to the ratio between the typical lipid distance in a biological membrane and 
the characteristic length of the COPII proteins in a cage51. For the membrane-scaffold interaction we employ 
a Lennard-Jones potential where the depth of the potential well is equal to εLJ. Starting from a pseudo-circular 
equilibrium configuration, where the scaffold does not perturb the membrane, we simulate the vesicle formation 
by changing gradually the equilibrium angle of the scaffold θs. The simulations are performed using the LAMMPS 
molecular dynamics simulator package64 with a constant NVE integration and the addition of a viscous damping 
force to reduce oscillations.
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